Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
October 6, 2025Pamplona/MadridIn recruitment
1479-0012 Clinical trial to find an appropriate dose of zongertinib in combination with trastuzumab deruxtecan or trastuzumab emtansine, and to test whether it helps people with different types of HER2 cancer that has spread
The primary objective is to characterize the safety, tolerability and dose-toxicity curve of zongertinib in combination with T-DXd or in combination with T-DM1 in patients with HER2 metastatic breast cancer (mBC) or metastatic gastric or gastroesophageal adenocarcinoma (mGEAC) by evaluating escalating dose levels with overdose monitoring to achieve the primary objective of determining maximum tolerated doses (MTDs) and/or doses for future development. -
September 29, 2025Pamplona/MadridIn recruitment
NAPISTAR 1-01 Clinical trial to investigate the safety, tolerability, pharmacokinetics and efficacy of TUB-040 in patients with platinum-resistant large malignant ovarian cancer or non-small cell lung cancer.
The objective of this study is to evaluate a new drug (TUB-040) in two phases for patients with ovarian cancer or non-small cell lung cancer. -
September 24, 2025Pamplona/MadridIn recruitment
-
September 22, 2025PamplonaIn recruitmentEarly phase
D798VC00001 Clinical trial to evaluate the safety and efficacy of new interventions and study combinations in participants with colorectal cancer.
The objective of this study is to learn more about the effectiveness and safety of the study drug, volrustomig (also called MEDI5752), given in combination with a reference treatment for colorectal cancer. -
September 22, 2025Pamplona/MadridIn recruitment
SGNTUC-029 Phase III, open-label, randomized study of tucatinib in combination with trastuzumab and mFOLFOX6 vs. mFOLFOX6 given with or without cetuximab or bevacizumab as first-line treatment for patients with HER2 metastatic colorectal cancer.
The objective of this study is to test how tucatinib, trastuzumab and mFOLFOX6 perform for the treatment of HER2-positive colon or rectal cancer compared to mFOLFOX6 alone or mFOLFOX6 together with bevacizumab or cetuximab. -
September 15, 2025PamplonaIn recruitmentEarly phase
RIVER-81 Clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical efficacy of RVU120 in combination with venetoclax in participants with AML in whom previous treatment with venetoclax and a hypomethylating agent failed (RIVER-81).
The objectives of this study are to: ¿ Understand the appropriate dose of the study treatment (RVU120 venetoclax) for the subsequent study; ¿ Understand the effect of the study drug in reducing AML; ¿ Assess the tolerability of the study treatment and identify any potential side effects associated with the study drug; ¿ Perform pharmacokinetic (PK) testing to understand how the study treatment is metabolized and eliminated from the body; ¿ Assess how the study ... -
September 10, 2025PamplonaIn recruitmentEarly phase
-
September 8, 2025PamplonaIn recruitmentEarly phase
OMTX705-004 Study of OMTX705 in combination with regorafenib and tislelizumab in patients with advanced or metastatic colorectal cancer
The objective of this trial is to test whether a new drug, OMTX705, is safe and well tolerated when used in conjunction with two other existing drugs: regorafenib (Stivarga®) and tislelizumab (Tevimbra®), and to determine the most appropriate dose of these drugs for use in future trials and further clinical development of OMTX705. -
September 3, 2025Pamplona/MadridIn recruitmentEarly phase
ZN-c3-005 Phase II clinical trial to evaluate the efficacy and safety of ZN-c3 in patients with high-grade serous ovarian, fallopian tube or primary peritoneal ovarian cancer
The main objective of this study is: Part 1b: To determine the safety and tolerability of ZN-c3 in PROC subjects Part 2: To investigate the antitumor activity of ZN-c3 in PROC subjects -
September 1, 2025PamplonaIn recruitment
AC220-168 Phase III, double-blind, randomized, placebo-controlled clinical trial of quizartinib administered in combination with induction and consolidation chemotherapy and as maintenance therapy in adult patients with a diagnosis of
The purpose of this trial is to learn more about an investigational drug called QUIZARTINIB. An investigational drug is a drug that is not approved to treat your disease. It is being studied to see if your disease or medical condition improves while you are receiving it and if it is safe for people who have the same disease as you.